Indication
Chorea
5 clinical trials
4 products
Product
ValbenazineClinical trial
Open-Label Study of Valbenazine for the Treatment of Chorea Associated With Huntington Disease in CanadaStatus: , Estimated PCD: 2026-03-01
Clinical trial
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseStatus: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington DiseaseStatus: Completed, Estimated PCD: 2021-10-15
Product
PlaceboClinical trial
Risperidone for the Treatment of Huntington's Disease ChoreaStatus: Completed, Estimated PCD: 2023-12-30
Product
RisperidoneClinical trial
Prospective Pilot Trial to Address the Feasibility and Safety of Treatment With Oral Zinc in GNAO1 Associated DisordersStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Product
Zinc Acetate